Indivior Gets FDA Approval For Faster Initiation Of Opioid-Dependence Treatment, More Injection Options

Indivior PLC, which specializes in addiction treatment, announced that the U.S. Food and Drug Administration (FDA) has approved label changes for SUBLOCADE® including a rapid initiation protocol and alternative injection sites, marking a significant advancement in the treatment of moderate to severe opioid use disorder (OUD). These FDA label changes can provide important benefits for patients and health care provider organizations. Rapid initiation may lessen some of the practical obstacles to treatment induction, which may increase the likelihood that consumers and provider organizations will start therapy quickly, thereby shortening the time to achieve SUBLOCADE’s therapeutic levels that provide . . .